Kim et al., 2018 - Google Patents
Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOPKim et al., 2018
- Document ID
- 2378631812898021676
- Author
- Kim S
- Go S
- Seo J
- Kang M
- Park S
- Kim H
- Lee G
- Publication year
- Publication venue
- Leukemia Research
External Links
Snippet
Objective We evaluated the clinical implications of the albumin to globulin ratio (AGR) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). Methods Data of …
- 206010012818 Diffuse large B-cell lymphoma 0 title abstract description 46
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP | |
| Lara-Guerra et al. | Phase II study of preoperative gefitinib in clinical stage I non–small-cell lung cancer | |
| Akamine et al. | Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers | |
| Ahn et al. | Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens | |
| Yoon et al. | Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma | |
| Moghadamyeghaneh et al. | Preoperative leukocytosis in colorectal cancer patients | |
| Pucciarelli et al. | Health-related quality of life outcomes in disease-free survivors of mid-low rectal cancer after curative surgery | |
| CN108315413A (en) | A kind of human liver cancer marker and application thereof | |
| Sakata et al. | Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors | |
| Takenaka et al. | Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non–small-cell lung cancer | |
| Seo et al. | Diagnostic and prognostic plasma biomarkers for idiopathic pneumonia syndrome after hematopoietic cell transplantation | |
| Miyazaki et al. | The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303 | |
| Khononov et al. | Host response to immune checkpoint inhibitors contributes to tumor aggressiveness | |
| Coosemans et al. | Increased immunosuppression is related to increased amounts of ascites and inferior prognosis in ovarian cancer | |
| US20190219580A1 (en) | Methods of drug therapy selection for breast cancer patients based on her2 and her3 pathway subtyping | |
| Yabe et al. | Association between skin flap necrosis and sarcopenia in patients who underwent total mastectomy | |
| Li et al. | Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer | |
| Wood et al. | Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer | |
| Li et al. | Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma | |
| RU2670768C9 (en) | Tumour biomarker | |
| CN115078727A (en) | A marker, kit and application for predicting the effect of cancer immunotherapy | |
| Cheng et al. | MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer | |
| Fatima et al. | Circulatory proteins in women with breast cancer and their chemotherapeutic responses | |
| Lin et al. | A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients | |
| Liang et al. | Risk factors and their diagnostic values for ocular metastases in invasive ductal carcinoma |